Continuing on from last month's editorial on the dramatic changes which have occurred in stroke intervention over recent years, the continuation of this topic in this edition is a reflection of its importance in the evolving world of stroke management. Ringleb et al. present the results of their ECASS 4: EXTEND trial, in which they select patients for intravenous thrombolysis out to 9 h post-stroke onset, or those waking with stroke. While the primary outcome measure of difference in the mRS distribution at day 90 of 1.20 did not reach statistical significance, the estimate was in the right direction. There was only one symptomatic intracranial hemorrhage among the total of 119 randomized patients.
These important ECASS 4: EXTEND results were then included with the recently published and clearly positive EXTEND trial with a larger sample size of 225 patients and the 4.5-6 h data from the earlier EPITHET phase II trial to give an overall metanalysis of patients between 4.5 and 9 h including those waking with stroke. This metanalysis of a total of 414 patients clearly showed benefit of tPA over placebo with an adjusted odds ratio of 1.86 (95% confidence intervals 1.15-2.99, p ¼ 0.011). This was in the presence of an overall symptomatic intracranial hemorrhage rate of 4.7%, well within the acceptable range for a trial of iv thrombolysis.
The important principal in selecting patients with all of these trials in the extended time window period was the use of automated perfusion imaging to identify patients in whom viable penumbral tissue of a significant degree could be identified. Interestingly, while in the EPITHET and ECASS 4: EXTEND trials MRI DWI-PWI mismatch perfusion imaging was used, in the EXTEND trial, CT perfusion (CTP) was the dominant imaging modality, particularly during the later phases of the study. CTP is more broadly available, simpler and quicker to use than its MR counterpart and should become a standard part of the workup of patients presenting with acute stroke.
These are rapidly changing times in the management of stroke generally but particularly for interventions during the acute and hyper acute phases. The most important message to all stroke physicians and lay public is that in spite of the time window extension, both with iv thrombolysis and thrombectomy, earlier treatment means better outcomes, the mantra ''time is brain'' has never been so apposite!
